TXG

10x Genomics, Inc. NASDAQ

Healthcare ·Medical - Healthcare Information Services ·US · 10xgenomics.com

$22.01

Mkt Cap $2.8B

52w Low $7.72 76.3% of range 52w High $26.45

50d MA $21.38 200d MA $16.99

P/E (TTM) -64.1x

EV/EBITDA -15.5x

P/B 3.5x

Debt/Equity 0.2x

ROE -5.5%

P/FCF 15.6x

RSI (14) —

ATR (14) —

Beta 2.17

50d MA $21.38

200d MA $16.99

Avg Volume 2.6M

About

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its ch…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 12, 2026	AMC	-0.19	-0.13	+31.6%	17.51	+9.9%	+3.5%	+6.3%	+11.8%	+9.6%	+7.8%	—
Nov 6, 2025	AMC	-0.07	-0.22	-214.3%	13.00	+10.1%	+17.3%	+31.4%	+27.6%	+28.4%	+25.8%	—
Aug 7, 2025	AMC	-0.35	0.28	+180.0%	12.80	+13.2%	-4.0%	-3.8%	+0.1%	+6.0%	+3.4%	—
May 8, 2025	AMC	-0.45	-0.36	+20.0%	8.63	+12.5%	+1.6%	+10.0%	+11.8%	+5.7%	+6.6%	—
Feb 12, 2025	AMC	-0.29	-0.40	-37.9%	12.00	-7.1%	-0.5%	+2.7%	+0.6%	+0.8%	-3.7%	—
Oct 29, 2024	AMC	-0.34	-0.30	+11.8%	15.79	-2.7%	+4.4%	+1.5%	+3.4%	+6.3%	+9.8%	—
Aug 8, 2024	AMC	-0.47	-0.32	+31.9%	19.55	+9.7%	+4.5%	+0.5%	+10.1%	+1.1%	+15.8%	—
Apr 30, 2024	AMC	-0.46	-0.50	-8.7%	29.28	-9.5%	-8.1%	-10.2%	-6.1%	-6.9%	-10.7%	—
Feb 15, 2024	AMC	-0.36	-0.41	-13.9%	48.07	-2.0%	+0.8%	-1.3%	-3.0%	-5.2%	-6.4%	—
Nov 2, 2023	AMC	-0.45	-0.51	-13.3%	36.53	-1.5%	+8.7%	+5.8%	+6.8%	+3.8%	-0.1%	—
Aug 3, 2023	AMC	-0.39	-0.53	-35.9%	58.49	-3.8%	-4.2%	-4.8%	-7.3%	-10.5%	-11.2%	—
May 3, 2023	AMC	-0.38	-0.44	-15.8%	54.00	+4.1%	+1.3%	+0.5%	+0.9%	-1.4%	+0.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 20	BofA Securities	Maintains	Neutral → Neutral	—	$26.08	$25.85	-0.9%	-5.7%	-11.9%	-12.5%	-17.9%	-15.3%
Apr 20	Canaccord Genuity	Maintains	Buy → Buy	—	$26.08	$25.85	-0.9%	-5.7%	-11.9%	-12.5%	-17.9%	-15.3%
Apr 14	Barclays	Maintains	Overweight → Overweight	—	$23.58	$24.19	+2.6%	+5.2%	+7.5%	+7.0%	+10.6%	+4.3%
Apr 7	Citigroup	Maintains	Neutral → Neutral	—	$21.89	$21.77	-0.5%	-0.3%	+5.2%	+5.1%	+6.3%	+7.7%
Mar 31	William Blair	Upgrade	Market Perform → Outperform	—	$19.81	$21.00	+6.0%	+7.2%	+11.3%	+12.7%	+10.5%	+10.1%
Mar 2	Stifel	Maintains	Buy → Buy	—	$23.05	$22.43	-2.7%	+0.4%	-1.9%	-3.0%	-6.1%	-9.7%
Feb 20	UBS	Maintains	Neutral → Neutral	—	$19.19	$19.15	-0.2%	-1.6%	-1.6%	-0.5%	+2.4%	+15.3%
Feb 13	TD Cowen	Maintains	Hold → Hold	—	$17.51	$19.24	+9.9%	+3.5%	+6.3%	+11.8%	+9.6%	+7.8%
Feb 13	Stifel	Maintains	Buy → Buy	—	$17.51	$19.24	+9.9%	+3.5%	+6.3%	+11.8%	+9.6%	+7.8%
Jan 27	Leerink Partners	Maintains	Market Perform → Market Perform	—	$22.50	$22.06	-2.0%	-3.9%	-6.3%	-7.6%	-10.2%	-11.3%
Jan 16	Leerink Partners	Maintains	Market Perform → Market Perform	—	$21.20	$21.20	+0.0%	-3.2%	+4.0%	+7.0%	+9.4%	+5.6%
Jan 7	Leerink Partners	Maintains	Market Perform → Market Perform	—	$19.31	$19.15	-0.8%	+3.5%	-0.1%	+6.0%	+2.5%	+6.3%
Jan 7	TD Cowen	Maintains	Hold → Hold	—	$19.31	$19.15	-0.8%	+3.5%	-0.1%	+6.0%	+2.5%	+6.3%
Dec 22	Canaccord Genuity	Maintains	Buy → Buy	—	$16.05	$16.05	+0.0%	+5.5%	+2.8%	+4.0%	+2.7%	+0.6%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$15.46	$16.02	+3.6%	+1.9%	+1.6%	+1.9%	+3.5%	+3.8%
Dec 11	Citigroup	Downgrade	Buy → Neutral	—	$17.53	$16.98	-3.1%	-5.6%	-11.8%	-10.1%	-10.4%	-10.2%
Dec 2	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$18.08	$17.83	-1.4%	-0.8%	-1.2%	+0.4%	-1.7%	-3.4%
Nov 11	Piper Sandler	Maintains	Neutral → Neutral	—	$17.08	$17.00	-0.5%	-2.9%	-2.3%	-4.3%	-7.0%	-8.1%
Nov 7	UBS	Maintains	Neutral → Neutral	—	$13.00	$14.31	+10.1%	+17.3%	+31.4%	+27.6%	+28.4%	+25.8%
Nov 7	JP Morgan	Maintains	Neutral → Neutral	—	$13.00	$14.31	+10.1%	+17.3%	+31.4%	+27.6%	+28.4%	+25.8%
Nov 7	Barclays	Maintains	Overweight → Overweight	—	$13.00	$14.31	+10.1%	+17.3%	+31.4%	+27.6%	+28.4%	+25.8%
Nov 7	Canaccord Genuity	Maintains	Buy → Buy	—	$13.00	$14.31	+10.1%	+17.3%	+31.4%	+27.6%	+28.4%	+25.8%
Aug 12	Morgan Stanley	Maintains	Overweight → Overweight	—	$12.31	$12.50	+1.5%	+4.1%	+10.2%	+7.6%	+8.5%	+9.3%
Aug 8	UBS	Maintains	Neutral → Neutral	—	$12.80	$14.49	+13.2%	-4.0%	-3.8%	+0.1%	+6.0%	+3.4%
Aug 8	Barclays	Maintains	Overweight → Overweight	—	$12.80	$14.49	+13.2%	-4.0%	-3.8%	+0.1%	+6.0%	+3.4%
Jun 26	BofA Securities	Maintains	Neutral → Neutral	—	$11.66	$11.65	-0.1%	+0.3%	+0.6%	-0.7%	+3.4%	+11.6%
Jun 24	Barclays	Maintains	Overweight → Overweight	—	$10.79	$11.01	+2.0%	+0.9%	+8.1%	+8.4%	+8.7%	+7.3%
May 19	Morgan Stanley	Maintains	Overweight → Overweight	—	$9.39	$9.12	-2.9%	-4.9%	-3.3%	-11.4%	-9.1%	-13.0%
May 15	Stephens & Co.	Maintains	Overweight → Overweight	—	$9.12	$9.01	-1.2%	+0.9%	+3.0%	-2.1%	-0.4%	-8.8%
May 13	UBS	Maintains	Neutral → Neutral	—	$9.49	$9.61	+1.3%	+1.7%	-3.9%	-3.1%	-1.1%	-5.9%
May 12	Goldman Sachs	Maintains	Sell → Sell	—	$8.77	$9.30	+6.0%	+8.2%	+10.0%	+4.0%	+4.9%	+7.1%
May 12	Canaccord Genuity	Maintains	Buy → Buy	—	$8.77	$9.30	+6.0%	+8.2%	+10.0%	+4.0%	+4.9%	+7.1%
May 9	JP Morgan	Maintains	Neutral → Neutral	—	$8.63	$9.71	+12.5%	+1.6%	+10.0%	+11.8%	+5.7%	+6.6%
Apr 10	Barclays	Maintains	Overweight → Overweight	—	$8.67	$8.29	-4.4%	-11.2%	-7.6%	-4.5%	-5.9%	-7.4%
Mar 4	Citigroup	Maintains	Buy → Buy	—	$9.85	$9.49	-3.7%	+6.8%	+11.0%	+16.4%	+18.8%	+7.5%
Feb 14	Barclays	Maintains	Overweight → Overweight	—	$11.94	$12.01	+0.6%	+3.2%	+1.1%	+1.3%	-3.2%	-8.7%
Feb 14	Morgan Stanley	Maintains	Overweight → Overweight	—	$11.94	$12.01	+0.6%	+3.2%	+1.1%	+1.3%	-3.2%	-8.7%
Feb 13	Canaccord Genuity	Maintains	Buy → Buy	—	$12.00	$11.15	-7.1%	-0.5%	+2.7%	+0.6%	+0.8%	-3.7%
Feb 13	JP Morgan	Maintains	Neutral → Neutral	—	$12.00	$11.15	-7.1%	-0.5%	+2.7%	+0.6%	+0.8%	-3.7%
Feb 13	Leerink Partners	Downgrade	Outperform → Market Perform	—	$12.00	$11.15	-7.1%	-0.5%	+2.7%	+0.6%	+0.8%	-3.7%
Feb 13	Citigroup	Maintains	Buy → Buy	—	$12.00	$11.15	-7.1%	-0.5%	+2.7%	+0.6%	+0.8%	-3.7%
Feb 13	Stifel	Maintains	Buy → Buy	—	$12.00	$11.15	-7.1%	-0.5%	+2.7%	+0.6%	+0.8%	-3.7%
Feb 13	UBS	Maintains	Neutral → Neutral	—	$12.00	$11.15	-7.1%	-0.5%	+2.7%	+0.6%	+0.8%	-3.7%
Feb 10	Barclays	Maintains	Overweight → Overweight	—	$14.25	$13.43	-5.8%	-15.4%	-17.1%	-15.8%	-16.2%	-13.5%
Jan 13	Morgan Stanley	Maintains	Overweight → Overweight	—	$15.58	$16.40	+5.3%	+0.8%	-0.9%	-3.9%	-3.1%	-3.2%
Nov 1	Barclays	Maintains	Overweight → Overweight	—	$16.03	$16.23	+1.2%	+1.9%	+4.7%	+8.2%	+3.6%	+0.9%
Oct 30	Citigroup	Maintains	Buy → Buy	—	$15.79	$15.36	-2.7%	+4.4%	+1.5%	+3.4%	+6.3%	+9.8%
Oct 30	UBS	Maintains	Neutral → Neutral	—	$15.79	$15.36	-2.7%	+4.4%	+1.5%	+3.4%	+6.3%	+9.8%
Oct 30	JP Morgan	Maintains	Neutral → Neutral	—	$15.79	$15.36	-2.7%	+4.4%	+1.5%	+3.4%	+6.3%	+9.8%
Oct 30	Goldman Sachs	Maintains	Sell → Sell	—	$15.79	$15.36	-2.7%	+4.4%	+1.5%	+3.4%	+6.3%	+9.8%

Recent Filings

8-K

10x Genomics, Inc. -- 8-K Filing

10x Genomics reported flat Q4 2025 revenue growth of 1% year-over-year at $166 million, signaling slowing momentum that investors should monitor against 2026 guidance expectations.

Feb 12

Data updated apr 27, 2026 6:15am · Source: massive.com